Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study

Cell Rep Med. 2023 Oct 17;4(10):101195. doi: 10.1016/j.xcrm.2023.101195. Epub 2023 Sep 15.

Abstract

It is unknown if vaccination affects the risk of post-COVID-19 cardiovascular diseases (CVDs). Therefore, this retrospective cohort study examines the short-term and long-term risks of post-infection CVD among COVID-19 patients with different vaccination status utilizing data from electronic health databases in Hong Kong. Cox proportional hazards regression adjusted with inverse probability of treatment weighting is used to evaluate the risks of incident CVD (coronary heart disease, stroke, heart failure) and all-cause mortality in COVID-19 patients. Compared with unvaccinated patients, vaccinated patients have a lower risk of CVD and all-cause mortality, and the lowest risk is observed in those who completed three doses of vaccine. Similar patterns in the subgroups of different vaccine platforms, age, gender, Charlson comorbidity index, and disease severity are observed. These findings highlight a positive dose-response relationship between overall CVD risk reduction and the number of vaccine doses received.

Keywords: SARS-CoV-2; inactivated vaccine; incident CVD; long COVID; omicron; post-COVID CVD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BNT162 Vaccine
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Cardiovascular Diseases* / epidemiology
  • Cohort Studies
  • Humans
  • Retrospective Studies
  • Vaccination

Substances

  • BNT162 Vaccine
  • sinovac COVID-19 vaccine